Any of you heard about the inhibitor RMC-7977?

Link to study - way more complicated than I can summarize.

For anyone interested in KRAS trials, also look up RM 9805. A trial specific to KRAS G12D, most commonly found in Adenocarcinoma.
I am considering this trial.

@annsant, from the abstract that @mayoconnectuser1 provided it appears that these promising new treatments are still in early stages. So far testing has been in vitro (in petri dishes) and in vivo (in mice). Next steps will be multiple phases of human trials.

Tagging @stageivsurvivor, who may have further insights.

There are two trials that are unique in that they are “pan” KRAS targeted therapies. They have the capability of targeting all KRAS variants, not just a specific one. Revolution Medicine’s RMC-6236 has some limited positions open. It is a phase Ia/Ib dose escalation study. This trial filled fast. There are some limited spaces open.

Another trial drug that also is a “pan” KRAS targeted therapy is RSC-1255 made by Rascal Therapeutics. This is in a phase Ia/Ib dose escalation phase and recruiting.
https://classic.clinicaltrials.gov/ct2/show/NCT04678648

Both of these drugs act upstream of the KRAS variants by interrupting the cell signaling pathway at the RAS gene one level above. By blocking the cell signaling pathway there, all variants below it would be prevented from receiving a signal to continue growth and proliferation. As a result, the cell enters apoptosis (programmed cell death) and dies.

@stageivsurvivorare you familiar with RM9805? If you read about it, would you say it is the same type of process but more targeted?

RMC-9805 works the same but is specific only to the G12D variant and no others. RMC-6236 and RSC-1255 works across all KRAS variants.

RMC-7977 is the latest of small molecule drugs coming out of Revolution Medicine targeting KRAS mutations. There has only been pre-clinical results from testing in mouse models. The results were published in the Journal Nature last week and the senior author of the paper was Ken Olive PhD of Columbia University. He is an extremely talented pancreatic cancer researcher that was mentored by David Tuveson, MD-PhD who is the director of Cold Spring Harbor Cancer Research Labs. I’ve attended a couple of lectures given by Dr. Olive. While working under Dr. Tuveson, he developed the mouse model now used in pre-clinical pancreatic cancer research.
The next step is in Revolution Medicine working in partnership with academic medical centers to initiate a phase I clinical trial. This won’t happen overnight as there is a lot of legwork that goes into the planning, development and initiation of human clinical trials. Columbia Presbyterian may likely be one of the first sites for conducting a trial of RMC-7977.

Another clinical trial for patients with KRAS mutations is from Elico Pharmaceutical addressing potential high risk of relapse in patient’s initially treated by surgery and chemo having any of seven KRAS sub-types. It involves a vaccine targeting immune cells in the lymph nodes, particularly CD4+ and CD8+ lymphocytes to stimulate a more robust response of the immune system should they encounter malignant cells harboring KRAS mutations G12A, C, D, R, S, V and G13D. The trial is ELI-002 7P and is a phase I/II trial currently recruiting for the phase I dose escalation study. If it is observed that participants enrolled in This trial are found to exhibit progression, they will be permitted to cross over to ELI-002 trial to see if they will benefit from it.

https://classic.clinicaltrials.gov/ct2/show/NCT05726864
.
https://classic.clinicaltrials.gov/ct2/show/NCT04853017

Cross-reference to recent, related post:
https://connect.mayoclinic.org/discussion/rmc-6236/?pg=1#comment-1051484

Also related, from : https://www.nasdaq.com/press-release/revolution-medicines-presents-encouraging-clinical-data-for-rmc-6236-and-rmc-6291-at

"About Revolution Medicines, Inc.Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-0708 (KRASQ61H) and RMC-5127 (KRASG12V) which are currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1)."

^Not an advertisement or endorsement of any kind. I have no financial connection or conflicting interests in the medical business.

Thank you for this information!
Is there anything we can do to streamline this process of getting universities setup for these clinical trials (request that PANCAN get involved, write to our congresspeople, write to universities, etc.)?